Jacob Sands, MD

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

Dr Jacob Sands discusses first-look OS and PFS data for tarlatamab plus durvalumab maintenance from the phase 3 DeLLphi-305 trial at ESMO 2026.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as first-line maintenance in SCLC.

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which involves tailored strategies including rinses, eye drops, and close monitoring.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

Jacob Sands, MD, discusses the inclusion of Dato-DXd into the treatment landscape of EGFR-mutant NSCLC.